State/Industry Medicine Pricing Agreements, Cost Savings and Counterfactuals: the Case of Ireland

Paul Gorecki

The Economic and Social Review, 2018, vol. 49, issue 1, 111-126

Abstract: Ireland’s Minister for Health claimed cumulative savings of €600 million for the 2016-2020 framework agreement with the Irish Pharmaceutical Healthcare Association. These savings are estimated using an implausible counterfactual of no agreement, since multiannual State/industry agreements are longstanding, while, since 2013, the State has powers to set medicine prices. A better counterfactual is the status quo: replicating the 2012-2015 agreement and extending its term for one year. This alternative counterfactual results in estimated cumulative savings of only €290 million. Greater transparency and more prudent choice of comparator for savings estimates would provide confidence in the estimates and more accurately demonstrate the likely savings that will be achieved.

Keywords: pharmaceuticals; prices; Ireland (search for similar items in EconPapers)
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.esr.ie/article/view/862/181 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eso:journl:v:49:y:2018:i:1:p:111-126

Access Statistics for this article

More articles in The Economic and Social Review from Economic and Social Studies
Bibliographic data for series maintained by Aedin Doris ().